{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:36:42Z","timestamp":1794472602343,"version":"4.9.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were treated with dual antiplatelet therapy (DAPT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Platelet aggregation was assessed by impedance aggregometry in patients with CCS receiving DAPT (aspirin plus clopidogrel). We compared the platelet reactivity in patients with a normal weight versus overweight or obese patients. Furthermore, the correlation between the body mass index (BMI) and adenosine diphosphate- (ADP-) or thrombin receptor-activating peptide- (TRAP-) dependent platelet aggregation was analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>64 patients were included in the study of which 35.9% were patients with normal weight. A higher ADP- and TRAP-dependent platelet reactivity was observed in overweight and obese patients (ADP: median 27 units (U) [IQR 13\u201339.5] vs. 7 U [6\u201315], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and TRAP: 97 U [73\u2013118.5] vs. 85 U [36\u2013103], <jats:italic>p<\/jats:italic>\u2009=\u20090.035). Significant positive correlations were observed between agonist-induced platelet reactivity and BMI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite the use of DAPT, a higher platelet reactivity was found in overweight and obese patients with CCS. If these patients will benefit from treatment with more potent platelet inhibitors, it needs to be evaluated in future clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-022-07325-z","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T03:02:50Z","timestamp":1645758170000},"page":"833-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel"],"prefix":"10.1007","volume":"37","author":[{"given":"Marianna","family":"Puccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Friebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-7644","authenticated-orcid":false,"given":"Ursula","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"7325_CR1","doi-asserted-by":"crossref","unstructured":"Barrachina MN, Moran LA, Izquierdo I, et al. Analysis of platelets from a diet-induced obesity rat model: elucidating platelet dysfunction in obesity. Sci Rep. 2020.","DOI":"10.1038\/s41598-020-70162-3"},{"key":"7325_CR2","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2021."},{"key":"7325_CR3","doi-asserted-by":"crossref","unstructured":"Rosito GA, D\u2019Agostino RB, Massaro J, et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost. 2004.","DOI":"10.1160\/TH03-01-0014"},{"key":"7325_CR4","doi-asserted-by":"crossref","unstructured":"Badimon L, Hernandez Vera R, Padro T, Vilahur G. Antithrombotic therapy in obesity. Thromb Haemost. 2013.","DOI":"10.1160\/TH12-12-0928"},{"key":"7325_CR5","doi-asserted-by":"crossref","unstructured":"Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017.","DOI":"10.1093\/eurheartj\/ehx181"},{"key":"7325_CR6","doi-asserted-by":"crossref","unstructured":"Bordeaux BC, Qayyum R, Yanek LR, et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol. 2010.","DOI":"10.1111\/j.1751-7141.2009.00058.x"},{"key":"7325_CR7","doi-asserted-by":"crossref","unstructured":"Ranucci M, Aloisio T, Dedda UD, et al. Platelet reactivity in overweight and obese patients undergoing cardiac surgery. Platelets. 2019.","DOI":"10.1080\/09537104.2018.1492108"},{"key":"7325_CR8","doi-asserted-by":"crossref","unstructured":"Campello E, Spiezia L, Zabeo E, et al. Hypercoagulability detected by whole blood thromboelastometry (ROTEM(R)) and impedance aggregometry (MULTIPLATE(R)) in obese patients. Thromb Res. 2015.","DOI":"10.1016\/j.thromres.2015.01.003"},{"key":"7325_CR9","unstructured":"Multiplate Analyzer, Roche Series. Multiplate Analyzer, Roche 2021. https:\/\/www.roche.de\/diagnostik-produkte\/produktkatalog\/systeme\/multiplate-analyzer\/. Accessed 2021 06 nov."},{"key":"7325_CR10","doi-asserted-by":"crossref","unstructured":"Schuette C, Steffens D, Witkowski M, et al. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc Diabetol. 2015.","DOI":"10.1186\/s12933-015-0182-7"},{"key":"7325_CR11","doi-asserted-by":"crossref","unstructured":"Verdoia M, Pergolini P, Rolla R, et al. Platelet larger cell ratio and high-on treatment platelet reactivity during dual antiplatelet therapy. Cardiovasc Drugs Ther. 2015.","DOI":"10.1007\/s10557-015-6616-3"},{"key":"7325_CR12","doi-asserted-by":"crossref","unstructured":"Verdoia M, Pergolini P, Rolla R, et al. Gender differences in platelet reactivity in patients receiving dual antiplatelet therapy. Cardiovasc Drugs Ther. 2016.","DOI":"10.1007\/s10557-016-6646-5"},{"key":"7325_CR13","doi-asserted-by":"crossref","unstructured":"Bobbert P, Stellbaum C, Steffens D, et al. Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy. Blood Coagul Fibrinolysis. 2012.","DOI":"10.1097\/MBC.0b013e32835824b3"},{"key":"7325_CR14","doi-asserted-by":"crossref","unstructured":"Pankert M, Quilici J, Loundou AD, et al. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. Am J Cardiol. 2014.","DOI":"10.1016\/j.amjcard.2013.09.011"},{"key":"7325_CR15","doi-asserted-by":"crossref","unstructured":"Deharo P, Pankert M, Bonnet G, et al. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. Int J Cardiol. 2014.","DOI":"10.1016\/j.ijcard.2014.07.228"},{"key":"7325_CR16","doi-asserted-by":"crossref","unstructured":"Gaglia MA Jr, Torguson R, Pakala R, et al. Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity. Am J Cardiol. 2011.","DOI":"10.1016\/j.amjcard.2011.04.029"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07325-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07325-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07325-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:15:07Z","timestamp":1690971307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07325-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7325"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07325-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"7 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}